Rifaximin dose-finding study for the treatment of small intestinal bacterial overgrowth.
Aliment Pharmacol Ther
; 22(1): 31-5, 2005 Jul 01.
Article
em En
| MEDLINE
| ID: mdl-15963077
ABSTRACT
BACKGROUND:
Few controlled studies assessing choice and duration of antibiotic therapy for small intestinal bacterial overgrowth are available.AIM:
To assess efficacy, safety and tolerability of different doses of rifaximin, a broad spectrum non-absorbable antibiotic, for intestinal bacterial overgrowth eradication.METHODS:
We enrolled 90 consecutive patients affected by small intestinal bacterial overgrowth. The presence of small intestinal bacterial overgrowth was based on the occurrence of a rise of H2 values >12 p.p.m. above the basal value after 50 g glucose ingestion. Patients were randomized in three 7-day treatment groups rifaximin 600 mg/day (group 1); rifaximin 800 mg/day (group 2) and rifaximin 1200 mg/day (group 3). Glucose breath test was reassessed 1 month after the end of therapy. Compliance to the treatment and incidence of side-effects were also evaluated.RESULTS:
No drop-outs were observed in the three groups. Glucose breath test normalization rate was significantly higher in group 3 (60%) with respect to group 1 (17%; P < 0.001) and group 2 (27%, P < 0.01). No significant differences in patient compliance and incidence of side-effects were found among groups.CONCLUSIONS:
Higher doses of rifaximin lead to a significant gain in terms of therapeutic efficacy in small intestinal bacterial overgrowth eradication without increasing the incidence of side-effects.
Buscar no Google
Coleções:
01-internacional
Contexto em Saúde:
3_ND
Base de dados:
MEDLINE
Assunto principal:
Rifamicinas
/
Infecções Bacterianas
/
Fármacos Gastrointestinais
/
Gastroenteropatias
/
Intestino Delgado
/
Antibacterianos
Tipo de estudo:
Clinical_trials
/
Diagnostic_studies
Limite:
Adult
/
Female
/
Humans
/
Male
Idioma:
En
Revista:
Aliment Pharmacol Ther
Ano de publicação:
2005
Tipo de documento:
Article